Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity

Efficient presentation of peptide‐MHC class I (pMHC‐I) complexes to immune T cells should benefit from a stable peptide‐MHC‐I interaction. However, it has been difficult to distinguish stability from other requirements for MHC‐I binding, for example, affinity. We have recently established a high‐throughput assay for pMHC‐I stability. Here, we have generated a large database containing stability measurements of pMHC‐I complexes, and re‐examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890–7901]. Using an affinity‐balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC‐I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC‐I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as “holes in the T‐cell repertoire” can be explained as being unstably bound to MHC‐I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC‐I. We conclude that the availability of accurate predictors of pMHC‐I stability might be helpful in the elucidation of MHC‐I restricted antigen presentation, and might be instrumental in future search strategies for MHC‐I epitopes.

[1]  S Brunak,et al.  Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.

[2]  J. McCluskey,et al.  The impact of HLA‐B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV , 2007, European journal of immunology.

[3]  D. Margulies,et al.  Measuring interactions of MHC class I molecules using surface plasmon resonance. , 1995, Journal of immunological methods.

[4]  Bjoern Peters,et al.  A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1 , 2007, The Journal of Immunology.

[5]  P. van Endert,et al.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition , 2009, Proceedings of the National Academy of Sciences.

[6]  J. Frelinger,et al.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Francisco A. Chaves,et al.  The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes , 2005, Immunological reviews.

[8]  A. Canella,et al.  Selective amino acid substitutions of a subdominant Epstein‐Barr virus LMP2‐derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein‐Barr virus‐associated malignancies , 1999, European journal of immunology.

[9]  Søren Buus,et al.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.

[10]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[11]  J. Yewdell,et al.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.

[12]  Morten Nielsen,et al.  CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. , 2007, Vaccine.

[13]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[14]  D. Margulies,et al.  Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity. , 1993, The Journal of biological chemistry.

[15]  B. Baker,et al.  Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer. , 2003, Biochemistry.

[16]  U. Grohmann,et al.  Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex , 1999, Cancer Immunology, Immunotherapy.

[17]  Francisco A. Chaves,et al.  The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. , 2005, Immunity.

[18]  C. Sylvester-Hvid,et al.  One-Pot, Mix-and-Read Peptide-MHC Tetramers , 2008, PloS one.

[19]  Yuzhang Wu,et al.  A naturally processed epitope on rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+ T cells. , 2009, Viral immunology.

[20]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[21]  A. Rickinson,et al.  HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.

[22]  J. Drijfhout,et al.  Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele 1 , 2009, The Journal of Immunology.

[23]  J. Yewdell,et al.  Cut and trim: generating MHC class I peptide ligands. , 2001, Current opinion in immunology.

[24]  J. Yewdell,et al.  High Peptide Affinity for MHC Class I does not Correlate with Immunodominance , 1999, Scandinavian journal of immunology.

[25]  D. Busch,et al.  MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. , 1998, Journal of immunology.

[26]  O. Lund,et al.  HLA Class I Binding 9mer Peptides from Influenza A Virus Induce CD4+ T Cell Responses , 2010, PloS one.

[27]  C. Sylvester-Hvid,et al.  Purification of correctly oxidized MHC class I heavy‐chain molecules under denaturing conditions: A novel strategy exploiting disulfide assisted protein folding , 2003, Protein science : a publication of the Protein Society.

[28]  Søren Brunak,et al.  Selecting Informative Data for Developing Peptide-MHC Binding Predictors Using a Query by Committee Approach , 2003, Neural Computation.

[29]  R. Offringa,et al.  Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. , 2009, Cancer research.

[30]  K. Parker,et al.  The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. , 1992, Journal of immunology.

[31]  S Brunak,et al.  SARS CTL Vaccine Candidates — HLA Supertype, Genome‐Wide Scanning and Biochemical Validation , 2004, Tissue antigens.

[32]  Søren Buus,et al.  A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules , 1994, European journal of immunology.

[33]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.

[34]  C. Sylvester-Hvid,et al.  Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds , 2001, European journal of immunology.

[35]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[36]  H. Grey,et al.  Free ligand-induced dissociation of MHC-antigen complexes. , 1991, Journal of immunology.

[37]  Hidde L. Ploegh,et al.  Peptide selection by MHC class I molecules , 1991, Nature.

[38]  Wilfried Bardet,et al.  Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. , 2004, Biochemistry.

[39]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[40]  K. Heeg,et al.  In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. , 1995, Vaccine.

[41]  A. Cope,et al.  Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes , 2002, European journal of immunology.

[42]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[43]  M. Nielsen,et al.  Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays , 2009, Journal of biomolecular screening.

[44]  A Sette,et al.  The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.

[45]  R. Tisch,et al.  Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. , 2001, Clinical immunology.

[46]  J. Sidney,et al.  Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues1 , 2004, The Journal of Immunology.

[47]  D Rognan,et al.  Use of fluorescence polarization to monitor MHC-peptide interactions in solution. , 2001, Journal of immunological methods.